Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain

✍ Scribed by Neil A. Hagen; Najib Babul

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 210 KB
• Volume: 79
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19970401)79:7<1428::aid-cncr21>3.0.co;2-0

✦ Synopsis

Fredphone, each given every 12 hours for 7 days. Pain intensity, nausea, and sedation erick, Pickering, Ontario, Canada.

were assessed by patients four times daily, and breakthrough analgesia was recorded.

RESULTS.

Thirty-one patients completed the study (18 women, 13 men; mean age, 56 { 3 years) and received a final controlled-release oxycodone dose of 124 { 22 mg per day and a final controlled-release hydromorphone dose of 30 { 6 mg per day. There were no significant differences between treatments in overall Visual Analogue Scale (VAS) pain intensity (VAS 28 { 4 mm vs. 31 { 4 mm), categorical pain intensity (1.4 { 0.1 vs. 1.5 { 0.1), daily rescue analgesic consumption (1.4 { 0.3 vs. 1.6 { 0.3), sedation scores (24 { 4 mm vs. 18 { 3 mm), nausea scores (15 { 3 mm vs. 13 { 3 mm), or patient preference. Two patients experienced hallucinations on controlled-release hydromorphone, but none did while receiving controlled-release oxycodone.

CONCLUSIONS.

Controlled-release oxycodone demonstrated excellent pharmacodynamic characteristics, analgesic efficacy, and safety as compared with controlled-release hydromorphone and represents an important new therapeutic op-Presented in part at the 8th World Congress tion for cancer pain management.